MedTrace Logo

A Clinical Study to Determine the Safety and Efficacy of An Oral Probiotic Supplementation in the Management of Irritable Bowel Syndrome With Protein Digestion.

NCT06687720 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-11-14

No results posted yet for this study

Summary

This is an open-label, two-arm, prospective, interventional, in-use safety and efficacy study of an oral probiotic supplementation in adult subjects having irritable bowel syndrome.

Conditions

  • Irritable Bowel Syndrome

Interventions

OTHER

MetBroma

Mode of Usage: Take one slow-release capsule twice a day, after meal Dosage Form: Capsule Unit Dose Route of administration: Oral frequency: Twice a day

Sponsors & Collaborators

  • Meteoric Biopharmaceuticals Pvt. Ltd.

    collaborator INDUSTRY

  • NovoBliss Research Pvt Ltd

    lead OTHER

Principal Investigators

  • Dr. Nayan K Patel · NovoBliss Research Pvt Ltd

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-30
Primary Completion
2024-11-30
Completion
2024-11-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06687720 on ClinicalTrials.gov